Pantoprazole
Gastroesophageal Reflux Disease
Children's Mercy Hospital Kansas CitySmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 89/ 100
Competitive context
1 Active assets in the Gastroesophageal Reflux Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lansoprazole Children's Mercy Hospital Kansas City | Phase 4 | BB |
Midazolam Children's Mercy Hospital Kansas City | Phase 4 | BB |
Dexlansoprazole National Cheng-Kung University Hospital | Phase 4 | BB |
Tannic Acid Hospital Infantil Cândido Fontoura | Phase 3 | BB |
Lidocaine Hospital Infantil Cândido Fontoura | Phase 3 | BB |
View all 17 →
Same molecule, other indications
Pantoprazole is also rated in:
metabolic dysfunction-associated steatotic liver diseaseDormant
B
Indicative · Phase 4
62 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →